Micron Technology: HBM Sold Out For 2026, Wall Street Is Still Underpricing

AI-driven HBM shift, 2026 sold-out contracts, rising margins and EPS amid low valuation. Read more macro analysis here.
News-Medical.Net on MSN

mAbxience selects Genedata Bioprocess to automate end-to-end CDMO workflows

Genedata, a Danaher company and the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that mAbxience has selected the Genedata Bioprocess ® enterprise ...